Literature DB >> 25110437

Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.

Takaomi Kessoku1, Yuji Ogawa1, Masato Yoneda1, Kento Imajo1, Yoshio Sumida1, Yuichiro Eguchi1, Hideki Fujii1, Hideyuki Hyogo1, Masafumi Ono1, Yasuaki Suzuki1, Takumi Kawaguchi1, Kazuaki Chayama1, Saiyu Tanaka1, Kazuma Fujimoto1, Keizo Anzai1, Toshiji Saibara1, Michio Sata1, Yoshito Itoh1, Atsushi Nakajima1, Takeshi Okanoue1.   

Abstract

AIM: To investigate a simple noninvasive scoring system for predicting liver cirrhosis in nonalcoholic fatty liver disease (NAFLD) patients.
METHODS: A total of 1048 patients with liver-biopsy-confirmed NAFLD were enrolled from nine hepatology centers in Japan (stage 0, 216; stage 1, 334; stage 2, 270; stage 3, 190; stage 4, 38). The weight and height of the patients were measured using a calibrated scale after requesting the patients to remove their shoes and any heavy clothing. Venous blood samples were obtained in the morning after the patients had fasted overnight for 12 h. Laboratory evaluation was performed in all patients. Statistical analysis was conducted using SPSS version 12.0. Continuous variables were expressed as mean ± SD.
RESULTS: The optimal cutoff value of platelet count, serum albumin, and aminotransferase/alanine aminotransferase ratio (AAR) was set at < 15.3 10(4)/μL, < 4.0 g/dL, and > 0.9, respectively, by the receiver operating characteristic curve. These three variables were combined in an unweighted sum (platelet count = 1 point, serum albumin = 1 point, AAR = 1 point) to form an easily calculated composite score for predicting cirrhosis in NAFLD patients, called the PLALA (platelet, albumin, AAR) score. The diagnosis of PLALA ≥ 2 had sufficient accuracy for detecting liver cirrhosis in NAFLD patients.
CONCLUSION: The PLALA score may be an ideal scoring system for detecting cirrhosis in NAFLD patients with sufficient accuracy and simplicity to be considered for clinical use.

Entities:  

Keywords:  Alanine aminotransferase ratio; Albumin; Cirrhosis; Fibrosis; Nonalcoholic fatty liver disease; Platelet

Mesh:

Substances:

Year:  2014        PMID: 25110437      PMCID: PMC4123339          DOI: 10.3748/wjg.v20.i29.10108

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 3.  Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography.

Authors:  Massimo Pinzani; Francesco Vizzutti; Umberto Arena; Fabio Marra
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-02

4.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Takayuki Nakagawa; Hiroya Taniguchi; Kota Fujii; Tatsushi Omatsu; Tomoaki Nakajima; Hiroshi Sarui; Makoto Shimazaki; Takahiro Kato; Junichi Okuda; Kazunori Ida
Journal:  Ann Intern Med       Date:  2005-11-15       Impact factor: 25.391

6.  Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease.

Authors:  Raphael B Merriman; Linda D Ferrell; Marco G Patti; Shiobhan R Weston; Mark S Pabst; Bradley E Aouizerat; Nathan M Bass
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

7.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

Review 8.  Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?

Authors:  Geoffrey C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2003-02       Impact factor: 4.029

9.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

Authors:  S A Harrison; D Oliver; H L Arnold; S Gogia; B A Neuschwander-Tetri
Journal:  Gut       Date:  2008-04-04       Impact factor: 23.059

10.  The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.

Authors:  Neeraj Bhala; Paul Angulo; David van der Poorten; Eric Lee; Jason M Hui; Giorgio Saracco; Leon A Adams; Phunchai Charatcharoenwitthaya; Joanne H Topping; Elisabetta Bugianesi; Christopher P Day; Jacob George
Journal:  Hepatology       Date:  2011-08-09       Impact factor: 17.425

View more
  6 in total

Review 1.  Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis.

Authors:  Qing Pang; Kai Qu; Jian-Bin Bi; Su-Shun Liu; Jing-Yao Zhang; Si-Dong Song; Ting Lin; Xin-Sen Xu; Yong Wan; Ming-Hui Tai; Hao-Chen Liu; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

2.  Nonalcoholic Fatty Liver Disease: Correlation of the Liver Parenchyma Fatty Acid with Intravoxel Incoherent Motion MR Imaging-An Experimental Study in a Rat Model.

Authors:  Seung-Man Yu; Sung Hwan Ki; Hyeon-Man Baek
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

Review 3.  Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.

Authors:  Masato Yoneda; Kento Imajo; Hirokazu Takahashi; Yuji Ogawa; Yuichiro Eguchi; Yoshio Sumida; Masashi Yoneda; Miwa Kawanaka; Satoru Saito; Katsutoshi Tokushige; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2017-11-24       Impact factor: 7.527

4.  Impact of steatosis and inflammation definitions on the performance of NASH tests.

Authors:  Thierry Poynard; Mona Munteanu; Frederic Charlotte; Hugo Perazzo; Yen Ngo; Olivier Deckmyn; Raluca Pais; Philippe Mathurin; Vlad Ratziu
Journal:  Eur J Gastroenterol Hepatol       Date:  2018-04       Impact factor: 2.566

5.  Cirrhosis in Wilson Disease is characterized by Impaired Hepatic Synthesis, Leukopenia and Thrombocytopenia.

Authors:  Hao-Jie Zhong; Ping Xiao; Da Lin; Hui-Min Zhou; Xing-Xiang He
Journal:  Int J Med Sci       Date:  2020-05-29       Impact factor: 3.738

6.  Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.

Authors:  Norio Akuta; Yusuke Kawamura; Yasuji Arase; Fumitaka Suzuki; Hitomi Sezaki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Satoshi Saitoh; Yoshiyuki Suzuki; Kenji Ikeda; Hiromitsu Kumada
Journal:  Gut Liver       Date:  2016-05-23       Impact factor: 4.519

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.